Deuterated derivatives of psilocybin and uses thereof

Abstract

Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.

1 - 20 . (canceled) 
     
     
         21 . A pharmaceutical composition comprising a deuterated compound of structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof; 
         wherein the pharmaceutical composition comprises about 0.5 mg to 500 mg of the compound. 
       
     
     
         22 . The composition of  claim 21 , wherein the composition further comprises a pharmaceutically acceptable carrier. 
     
     
         23 . The composition of  claim 22 , wherein the composition is suitable for oral administration. 
     
     
         24 . The composition of  claim 22 , wherein the composition is suitable for intravenous (IV) administration. 
     
     
         25 . The composition of  claim 23 , wherein the composition is a solid dose composition. 
     
     
         26 . The composition of  claim 25 , wherein the solid dose composition is a tablet, capsule, granule, powder, sachet, or chewable. 
     
     
         27 . The composition of  claim 21 , wherein the composition comprises about 0.5 mg to about 250 mg of the deuterated compound, or a pharmaceutically acceptable salt thereof. 
     
     
         28 . The composition of  claim 27 , wherein the composition comprises about 0.5 mg to about mg of the deuterated compound, or a pharmaceutically acceptable salt thereof. 
     
     
         29 . The composition of  claim 28 , wherein the composition comprises about 10 mg to about mg of the deuterated compound, or a pharmaceutically acceptable salt thereof. 
     
     
         30 . The composition of  claim 22 , wherein the composition comprises about 0.01 mg/ml to about 50 mg/ml of the deuterated compound, or a pharmaceutically acceptable salt thereof. 
     
     
         31 . A method of treating a neurological or psychiatric disorder in a subject in need thereof, the method comprising administering an effective amount of a pharmaceutical composition comprising a deuterated compound of structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. 
       
     
     
         32 . The method of  claim 31 , wherein the disorder is a psychiatric disorder. 
     
     
         33 . The method of  claim 32 , wherein the psychiatric disorder is a depressive disorder or an eating disorder. 
     
     
         34 . The method of  claim 33 , wherein the depressive disorder is major depressive disorder or treatment-resistant depression. 
     
     
         35 . The method of  claim 31 , wherein the disorder is a neurological disorder. 
     
     
         36 . The method of  claim 35 , wherein the neurological disorder is a pain disorder. 
     
     
         37 . The method of  claim 31 , wherein the composition comprises the deuterated compound, or a pharmaceutically acceptable salt thereof. 
     
     
         38 . The method of  claim 37 , wherein the composition comprises about 0.5 mg to about 50 mg of the deuterated compound, or a pharmaceutically acceptable salt thereof. 
     
     
         39 . The method of  claim 37 , wherein the composition comprises about 10 mg to about 50 mg of the deuterated compound, or a pharmaceutically acceptable salt thereof. 
     
     
         40 . The method of  claim 31 , wherein the composition is administered orally.